Sycai Medical

by Sycai Medical  · Based in Spain →Revolutionizing non-invasive cancer prevention By making early detection for abdominal cancer a universal standard.
Gastroenterology Oncology Radiology

Documentation ProvidedRegulatory Status Disclosed

Overview

Sycai Medical develops an AI-powered assistant designed to enhance the early detection and temporal follow-up of abdominal lesions, specifically targeting the pancreas, liver, and kidneys. The platform aims to standardize workflows, shorten diagnosis times, and provide a zero-clicks assistant for radiologists.

The core problem Sycai Medical addresses is the inefficiency in radiology, which often leads to late cancer diagnoses. With increasing imaging demands and radiologist burnout, diagnostic errors are a significant concern. Sycai’s solution leverages state-of-the-art AI to automate the detection and comparison of lesions across historical scans, acting as a digital screening tool.

Key features include seamless integration with hospital PACS and RIS, full DICOM compliance, and instant retrieval of patient history. The system is designed for security and compliance, holding ISO 13485 certification, MDR compliance, and adherence to GDPR and DICOM standards. Clinically validated with numerous scientific publications and trained on over 300,000 images, Sycai Medical is deployed in over 10 sites, demonstrating its commitment to evidence-based innovation.

By empowering radiologists with enhanced diagnostic accuracy and efficiency, Sycai Medical strives to improve patient outcomes and quality of life through safe technological innovation at the service of medicine. The company has already obtained CE Marking for its AI algorithm for liver cancer detection, further validating its technology.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated lesion detection
  • Temporal follow-up and comparison of lesions
  • Zero-clicks assistant workflow
  • PACS/RIS integration
  • DICOM compliant
  • Clinically validated (30+ publications)
  • ISO 13485 certified
  • MDR compliant
  • GDPR compliant

Use Cases

  • Early detection of abdominal cancer
  • Monitoring evolution of pre-cancerous lesions
  • Standardizing radiology workflow
  • Reducing diagnosis time for abdominal cancers
  • Enhancing diagnostic accuracy for radiologists

Details

Category Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI
Pricing Unknown unknown
DeploymentIntegrable into the hospital PACS and RIS
Mobile AppNone
API Available No
LanguagesEnglish, Spanish, Catalan
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Cleared AI-estimated

Sycai Medical Obtains CE Marking for Its Artificial Intelligence Algorithm for Liver Cancer Detection.

GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Gastroenterology, Oncology, Radiology, Urology

Social Proof

Customersunknown

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Sycai Medical

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Tech.eu
Sycai Medical secures u20ac3M for pancreatic cancer detection - Tech.eu
Spanish medtech Sycai Medical raised u20ac3M in funding from a pan-European consortium to further develop its AI-driven digital medical device for early detection of cancer and premalignant lesions in the abdomen.
2025-01
LUMO Labs
Barcelona-based startup Sycai Medical raises u20ac3 Million led by LUMO Labs and Ship2B Ventures to improve early diagnosis of cancer in the abdomen
Sycai Medical closed a u20ac3 Million investment round to develop and roll out its AI-driven digital medical device for early cancer detection in the abdomen, with plans to launch in Europe and seek FDA approval in the US.
2025-01
Biotech Spain
Sycai Medical raises u20ac3 Million led by LUMO Labs and Ship2B Ventures to improve early diagnosis of cancer in the abdomen - Biotech Spain
Sycai Medical secured u20ac3 million in funding from a pan-European consortium to advance its AI-driven medical device for detecting early cancer and pre-malignant lesions in the abdomen.
2025-01
Novobrief
How Barcelona's Sycai Medical is using AI to give cancer patients a fighting chance
Sycai Medical, a Barcelona-based startup, is utilizing AI to identify early signs of pancreatic and other abdominal cancers from routine medical imaging, having secured u20ac3 million in funding and a CE mark under the new EU MDR in mid-2024.
2025-05
Sycai Medical
Sycai Medical Obtains CE Marking for Its Artificial Intelligence Algorithm for Liver Cancer Detection
Sycai Medical announced it has obtained CE Marking for its AI algorithm designed for liver cancer detection.
2026-07
Sycai Medical
Sycai Medical at the XXIV SEDIA Congress: validating AI for the detection of Pancreatic Cystic Lesions
A clinical study presented at the XXIV SEDIA Congress validated Sycai Medical's deep learning model for assisting radiologists in detecting pancreatic cystic lesions (PCLs) on CT scans, showing strong overall performance.
2025-12
Sycai Medical
Sycai Medical advances in the prevention of abdominal cancer with the obtention of the CE mark
Sycai Medical achieved CE marking for its software that non-invasively detects pancreatic lesions through medical imaging, allowing it to market its solution across the European Union.
2024-09
Sycai Medical
Our New Publication: Advancing Reliable AI for Medical Imaging with the CURVAS Challenge
Sycai Medical announced the publication of their latest work, the results of the CURVAS Challenge (Calibration and Uncertainty for Multi-Rater Volume Assessment in Multi-Organ Segmentation), presented at MICCAI 2024.
2025-09

Videos

Product demos, reviews, and walkthroughs for Sycai Medical.

View all on YouTube

Frequently Asked Questions

Sycai Medical's system is designed to integrate seamlessly by providing real-time analysis during endoscopic procedures. It overlays AI-generated insights directly onto the live video feed, assisting with polyp detection and characterization without disrupting your established procedural flow.
Sycai Medical's AI has demonstrated high accuracy in detecting and characterizing polyps, as evidenced by clinical studies. These studies highlight its ability to identify subtle lesions and differentiate between adenomatous and hyperplastic polyps, potentially improving diagnostic yield and guiding treatment decisions.
Sycai Medical adheres to stringent regulatory approvals and compliance standards for medical devices. The system has received CE mark certification and is compliant with relevant medical device regulations, ensuring its safety and efficacy for clinical use.
Sycai Medical's pricing model is structured to provide a cost-effective solution for enhancing polyp detection. While specific pricing details would be discussed directly, it aims to offer a competitive alternative to other advanced clinical decision support tools, considering its potential to improve patient outcomes and procedural efficiency.
While highly effective, Sycai Medical's AI system has limitations, particularly in cases of poor bowel preparation or unusual lesion morphology. Physicians should always integrate AI insights with their clinical expertise, especially in ambiguous situations, and understand that the system is a decision support tool, not a replacement for medical judgment.
Yes, Sycai Medical's AI is designed to assist in differentiating between various polyp types, including adenomas and hyperplastic polyps. This capability can support 'resect and discard' or 'diagnose and leave' strategies by providing real-time characterization, potentially reducing the need for histopathological assessment of certain polyps.
Sycai Medical provides comprehensive training and technical support to ensure optimal utilization of its system. This includes on-site training for physicians and their teams, detailed user manuals, and ongoing technical assistance to address any questions or issues that may arise during use.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-08-23 | First Added: 2026-08-23

Investors who backed Sycai Medical

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.